scout
|Articles|February 25, 2022

Current and Emerging Trends in Breast Cancer: HER2+ and HER2-Low

This publication provides a summary of key stakeholder insights on the role of antibody-drug conjugates in targeting HER2+ or HER2-low breast cancer and examines clinical trial data on treatment options for HER2+ breast cancer with brain metastases.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME